Molecular Haemato-oncology

If you have chosen to participate in any Molecular Haemato-oncology EQA programme except Chimerism you will receive a lyophilised cell-line/patient sample preparation for molecular analysis. Instructions for storage, reconstitution and use of the lyophilised sample will be included with the sample. Prior to reconstitution, the lyophilised cells are stable at ambient temperature however, once the cells are reconstituted they should be processed immediately.

Please note- all lyophilised samples provided within these programmes are for EQA purposes only.

If you have chosen to participate in the Chimerism programme (and in some circumstances Ig/TCR clonality trials) you will currently receive fresh blood samples. Upon receipt, these samples should be processed immediately to prevent any degradation of the DNA.

***New for 2025-2026***

As part of the continuous development of our EQA/PT provision we will be introducing several updates to our molecular haemato-oncology programmes in 2024-2025.

Extending Accreditation for MPN Diagnostic Testing

Following the successful consolidation of the JAK2 p.Val617Phe (V617F) Mutation Status and the Myeloproliferative Neoplasms Diagnostic Testing programmes for the 2024/2025 registration period we will be submitting the markers JAK2 exon 12, CALR and MPL for accreditation. Please note, EQA for the JAK2 V617F is already accredited.

Pilot Liquid Biopsy in DLBCL EQA Study

UK NEQAS LI hope to run small pilot study assessing the use of next generation sequencing based liquid biopsy testing in diffuse large B cell lymphoma if there are enough participants interested. Please contact us if you wish to be part of this study, please contact admin@ukneqasli.co.uk

Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia Accreditation

This programme has now achieved ISO 17043:2010 accreditation. Formal performance monitoring has now been introduced and the number of trial issues will increase from two to three.

Webinar plans 

We will be hosting more educational webinars this year. Please keep checking our website for further details.

Update to ISO 17043:2023

An update to the ISO 17043 standards, to which EQA/PT providers are accredited, was released in May 2023. There are major new sections on impartiality, risk and information management. EQA/PT providers have a three-year transition window to show compliance to the new standards. UK NEQAS LI are currently performing a gap analysis to identify areas where additional work will be required to demonstrate compliance in 2024/2025. 

Please see programme specific pages on our website for further details.

* denotes changes to the programme in 2025/2026

**The JAK2 p.V617F Mutation Status programme is now incorporated within the MPN DT programme. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are working towards accreditation for the other markers.